Diabetes drugs face off in major heart failure study
NCT ID NCT06980623
Summary
This study compares two existing diabetes medications (tirzepatide and semaglutide) to see which one better prevents heart failure hospitalizations and death in people who have both type 2 diabetes and a specific type of heart failure. Researchers will analyze health insurance records from 26,000 adults who started one of these medications between 2022 and 2024. The goal is to determine which drug provides better protection against serious heart complications in this high-risk group.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEART FAILURE are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Brigham and Women's Hospital
Boston, Massachusetts, 02120, United States
Conditions
Explore the condition pages connected to this study.